Alembic Pharmaceuticals Ltd (APLLTD)

Alembic Pharma Delivers Better-Than-Expected 4QFY24 Earnings - 14 May, 2024

Motilal Oswal has given a neutral rating to Alembic Pharma with a target price of Rs 960. The research report states that Alembic Pharma delivered better-than-expected 4QFY24 earnings, led by better gross margin and improved off-take in the API segment. After two consecutive years of weak financial performance, Alembic Pharma ended FY24 with 10%/14%/43% YoY growth in sales/EBIDTA/PAT to INR62b/INR9.3b/ INR6b.

Alembic Pharmaceuticals Q4 Revenue Up 7.86%, Profit Rises 16.79% YoY - 11 May, 2024

Alembic Pharmaceuticals reported a 7.86% increase in revenue and a 16.79% rise in profit YoY for Q4, with EPS at ₹9.07. However, the company experienced a decline in revenue and profit compared to the previous quarter. The stock delivered returns of 0.67% in the last week, 36.39% in the last 6 months, and 31.86% YTD. Analysts have varied ratings, with a consensus recommendation to Hold the stock.

Alembic Pharma Posts Strong Financial Results - 10 May, 2024

Alembic Pharmaceuticals reported strong financial results for FY24, with an 80% YoY growth in net profit, 10% rise in net sales, and 41% surge in EBITDA. The company plans to launch approximately 25 products in the US market and aims to achieve double-digit growth in its US business.

Alembic Pharma Receives EIR from US FDA - 06 May, 2024

Alembic Pharmaceuticals has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for its Oncology Formulation Facility located at Panelav in Gujarat. With this, Alembic now holds EIRs for all its US FDA-regulated facilities.

Alembic Pharma Breaks Out on the Upside - 03 May, 2024

After consolidating between 1025 and 930, Alembic Pharmaceuticals has broken out on the upside. Analysts recommend buying with a stop loss of Rs 1005 and target of Rs 1070.